NCT00038103 - Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Breast Neoplasms

Interventions

DRUG

Exemestane

Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.

DRUG

Celecoxib + Exemestane

Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.

Trial Locations (20)

11

Pfizer Investigational Site, Lima

34

Pfizer Investigational Site, Lima

1000

Pfizer Investigational Site, Brussels

Pfizer Investigational Site, Manila

2020

Pfizer Investigational Site, Antwerp

2610

Pfizer Investigational Site, Wilrijk

3000

Pfizer Investigational Site, Leuven

5000

Pfizer Investigational Site, Namur

41101

Pfizer Investigational Site, Pune

44280

Pfizer Investigational Site, Guadalajara

75204

Pfizer Investigational Site, Dallas

90610-000

Pfizer Investigational Site, Porto Alegre

01509-900

Pfizer Investigational Site, São Paulo

B1P 1P3

Pfizer Investigational Site, Sydney

Unknown

Pfizer Investigational Site, Bogotá

Pfizer Investigational Site, Santiago de Cali

500 082

Pfizer Investigational Site, Hyderabad

560 029

Pfizer Investigational Site, Bangalore

400 012

Pfizer Investigational Site, Mumbai

07760

Pfizer Investigational Site, Mexico City